Core Insights - Novo Nordisk is a leading global healthcare company specializing in diabetes care, with a strong portfolio of GLP-1 receptor agonists, modern insulins, and human insulins [1] - The company's obesity product, Wegovy, has significantly boosted sales, increasing from under $23 billion to nearly $48 billion in four years, with profits rising 125% from $1.65 to $3.82 per share [2] - Despite strong sales growth and a recent earnings beat, Wall Street analysts have lowered their earnings estimates for Novo Nordisk, with 2025 EPS consensus dropping from $3.84 to $3.57 [3] Sales and Profit Growth - Wegovy's approval by the FDA in June 2021 has led to multiple label expansions, contributing to the doubling of Novo Nordisk's sales [2] - The company's profits surged significantly during this period, reflecting the successful market penetration of Wegovy [2] Analyst Sentiment - Analysts have expressed concerns about future earnings, with estimates for 2026 EPS declining from $3.95 to $3.51, indicating a potential annual decline of 1.8% [3] - The average price target for Novo Nordisk among eight covering analysts is currently $52, with a range between $42 and $70 [5][7] Market Dynamics - The approval of oral Wegovy, the first GLP-1 obesity pill in the U.S., could influence market dynamics and potentially shift analyst outlooks [4][7] - The competitive landscape includes smaller biotech players and companies like Hims & Hers, which have experienced significant stock volatility due to regulatory influences [4][5]